Following the overwhelming vote in Parliament on 15 January 2019 defeating Theresa May’s Brexit deal, No Brexit is the preferred outcome for pharma, says Alexandra Annis, Managing Pharma Analyst at GlobalData, a leading data and analytics company.
In offering her view on the potential impact of the vote on the healthcare industry, Annis says: “Although May survived the vote of no confidence, the defeat of her Brexit deal provides substantial uncertainty for the UK healthcare industry with the potential for a ‘No Deal’ Brexit, an extension to the Brexit deadline, or even No Brexit. As of October 2018, ‘No Brexit’ was compellingly the best outcome of Brexit for pharma, as indicated by 60% of respondents in the pharmaceutical sector who participated in GlobalData’s survey on the impact of Brexit on the healthcare sector.
“The regulatory implications of the UK leaving the EEA, disruption to the cross-EU supply chain, and funding for research and manufacturing are just a few of the concerns for the UK healthcare industry after Brexit.
“The pharmaceuticals industry is one of the largest and most dynamic in the UK, and is a major contributor to the economy. As well as being the home to the pharmaceutical giants GlaxoSmithKline and AstraZeneca, many other leading international pharmaceuticals companies have sizeable operations in the UK marking substantial importance to the UK economy.”
- GlobalData’s Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018 provides in-house analyst expertise on the results of a 10 minutes survey of 135 GlobalData Pharma clients and prospects which was fielded from October 3, 2018 to October 19, 2018. Participants answered questions about how they expected Brexit to affect the healthcare sector, both within and outside of the UK.
Articles on this page reflect the views of the author and not necessarily of London4Europe